BiotechTube
Home/Satellos Bioscience/Frank Gleeson
FG

Frank Gleeson

President & Chief Executive Officer

Satellos Bioscience

Therapeutic Areas

Muscular DystrophyRegenerative Medicine

Satellos Bioscience Pipeline

DrugIndicationPhase
SAT-3153Duchenne Muscular Dystrophy (DMD)Phase 1

Leadership Team at Satellos Bioscience

DM
Dr. Michael Rudnicki
Chief Scientific Officer & Founder
DP
Dr. Philip Lambert
Chief Development Officer
DR
Dr. Ryan Wiley
Head of Strategy & Partnerships
DJ
Dr. John Mendlein
Chair of the Board of Directors
View full Satellos Bioscience profile